미국의 의약품 3자 물류 서비스 시장 규모, 점유율, 동향 분석 보고서(2025-2030년) : 제품 유형별, 온도별, 치료 영역별, 제조업체 규모별, 서비스별, 부문 예측

U.S. Pharmaceutical Third-party Logistics Services Market Growth & Trends:

The U.S. pharmaceutical third-party logistics services market size is expected to reach USD 75.41 billion by 2030 and it is anticipated to grow at a CAGR of 8.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven due to the growing demand for efficient and secure supply chain solutions, increasing complexity in pharmaceutical distribution, and the need for compliance with stringent regulatory standards. Moreover, the rise in demand for temperature-sensitive and specialty drugs, such as biologics and vaccines, has heightened the importance of cold chain logistics, prompting pharmaceutical companies to rely on 3PL providers for advanced storage and transportation solutions.

Furthermore, is the development of advanced technologies to improve the efficiency and security of drug distribution is also contributing to the market growth. As pharmaceutical logistics operations become more complex, there is a growing reliance on automated data reporting systems to streamline compliance and performance monitoring. Automated reporting solutions help pharmaceutical 3PL providers generate real-time, accurate reports on key performance indicators (KPIs) such as on-time delivery rates, product condition, and regulatory compliance. These systems also automate the generation of reports required by regulatory bodies, reducing manual effort and ensuring that all necessary documentation is submitted on time.

In addition, the growing demand for temperature-sensitive pharmaceuticals and biopharmaceuticals is significantly fueling the expansion of the cold chain logistics market. Growing demand for the safe storage and transportation of these delicate products has led the companies to innovative cold chain solutions that safeguard product quality and efficacy. Moreover, increasing technological advancements by integrating artificial intelligence is further boosting the demand for cold chain logistics in the pharmaceutical sector. According to an article published by Pharmaceutical Commerce in October 2024, artificial intelligence (AI) has the potential to revolutionize the logistics of temperature-sensitive pharmaceuticals shipped through the cold chain in several transformative ways. AI can enhance the supply chain's efficiency and reliability through predictive analytics, real-time monitoring, and optimization of routes and resources.

Some of the key players in the market are Cencora Corporation, Kuehne+Nagel, Kerry Logistics Network Limited, Cardinal Health, McKesson Corporation, Thermo Fisher Scientific, among others. Market players are adopting key strategic initiatives to boost their market presence and expand their business. For instance, in April 2023, Kuehne+Nagel announced a 400,000 sq. ft. contract logistics fulfillment center near Dallas/Fort Worth International Airport. Positioned three miles from the terminals, the facility highlighted the company's strategic investment in healthcare logistics, designed to serve multiple clients with state-of-the-art capabilities.

U.S. Pharmaceutical Third-party Logistics Services Market Report Highlights:

• Based on product, the branded drugs segment dominated the market in 2024 due to growing incidence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions. The increasing cases of these condition have led to the rising demand for branded drugs in the U.S.
• Based on the temperature, ambient held the largest revenue share in 2024. Ambient storage is essential for products that do not require refrigeration or freezing, such as certain oral medications, over-the-counter drugs, among others.
• Based on the therapeutic area, oncology held the largest revenue share in 2024. The market for the segment is likely to expand with an increasing number of cancer cases across the country. Furthermore, recent trends have shown a shifting focus towards pharmaceutical products with significant advancements made in the treatment of cancer.
• Based on the manufacturer size, large held the largest revenue share in 2024. The large manufacturers have extensive resources and established supply chains. These companies typically have significant production capacities and a broad portfolio of products, which allows them to negotiate favorable terms with logistics providers.
• Based on the service, storage and shipping held the largest revenue share in 2024. With the increasingly competitive business landscape and complex process, several pharmaceutical companies are constantly seeking new ways to optimize their supply chain productivity and ensure compliance with industry regulations, further adopting the 3PL storage and shipping services.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. The Rise of E-Commerce
    • 3.2.1.2. Growing Demand for Outsourcing Services
    • 3.2.1.3. Rising Demand for Cold Chain Logistics
    • 3.2.1.4. Growing Applications of Reverse Logistics in Biopharmaceutical Industry
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Operational Costs
    • 3.2.2.2. Compliance Issues While Outsourcing
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Product Type Movement Analysis
• 4.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
• 4.4. Branded
  • 4.4.1. Branded market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Generic
  • 4.5.1. Generic market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Biosimilar
  • 4.6.1. Biosimilar market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Vaccine
  • 4.7.1. Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Cell Therapy
  • 4.8.1. Cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Gene Therapy
  • 4.9.1. Gene therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Temperature Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Temperature Movement Analysis
• 5.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Temperature, 2018 to 2030 (USD Million)
• 5.4. Ambient
  • 5.4.1. Ambient market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Refrigerated
  • 5.5.1. Refrigerated market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Frozen
  • 5.6.1. Frozen market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Ultra-frozen/Deep-Frozen
  • 5.7.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Cryogenic
  • 5.8.1. Cryogenic market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Therapeutic Area Movement Analysis
• 6.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Cardiovascular Diseases
  • 6.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Infectious Diseases
  • 6.6.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Neurology
  • 6.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Nephrology
  • 6.9.1. Nephrology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Rheumatology
  • 6.10.1. Rheumatology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.11. Allergy/Asthma
  • 6.11.1. Allergy/Asthma market estimates and forecasts 2018 to 2030 (USD Million)
• 6.12. Gastroenterology
  • 6.12.1. Gastroenterology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.13. Ophthalmology
  • 6.13.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.14. Others
  • 6.14.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Manufacturer Size Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Manufacturer Size Movement Analysis
• 7.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Manufacturer Size, 2018 to 2030 (USD Million)
• 7.4. Large
  • 7.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Medium
  • 7.5.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Small
  • 7.6.1. Small market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market: Service Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Market; Service Movement Analysis
• 8.3. U.S. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 8.4. Storage and Shipping
  • 8.4.1. Storage and Shipping market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Order-to-cash
  • 8.5.1. Order-to-cash market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Title Model
  • 8.6.1. Title Model market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. DSCSA and Serialization Services
  • 8.7.1. DSCSA and Serialization Services market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Pharmaceutical Sampling
  • 8.8.1. Pharmaceutical Sampling market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. Others
  • 8.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Position Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. CEVA Logistics
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Service benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. Cencora Corporation (ICS)
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Service benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. DB SCHENKER
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Service benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Kuehne+Nagel
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Service benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Kerry Logistics Network Limited
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Service benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Cardinal Health
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Service benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. McKesson Corporation
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Service benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. EVERSANA.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Service benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Thermo Fisher Scientific Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Service benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Knipper Health
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Service benchmarking
    • 9.3.10.4. Strategic initiatives